問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳冠諭

Recruiting

List

17Cases

2024-10-01 - 2029-09-30

Phase III

Active
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

  • Condition/Disease

    Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Test Drug

    Tablets Soft capsules Infusion solutions

Participate Sites
6Sites

Recruiting6Sites

2025-11-01 - 2030-12-31

Phase III

Active
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

  • Condition/Disease

    Prostatic Neoplasms, Castration-Resistant

  • Test Drug

    Intravenous infusion solution Intravenous infusion solution Tablets

Participate Sites
5Sites

Recruiting5Sites

2020-07-22 - 2027-11-10

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-01-01 - 2029-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-06-01 - 2028-03-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-01-01 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-01-01 - 2024-07-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2020-08-01 - 2025-04-07

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting4Sites

Terminated4Sites

2024-12-17 - 2030-08-23

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-11-01 - 2031-07-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB